RGD Reference Report - Systemic dexmedetomidine attenuates mechanical allodynia through extracellular sign db type 2 diabetic mice. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Systemic dexmedetomidine attenuates mechanical allodynia through extracellular sign db type 2 diabetic mice.

Authors: Chen, Hui  Xu, Xiang  Yang, Xiao-Yu  Ling, Bing-Yu  Sun, He-Ping  Liu, Chao  Zhang, Yu Qiu  Cao, Hong  Xu, Lan 
Citation: Chen H, etal., Neurosci Lett. 2017 Sep 14;657:126-133. doi: 10.1016/j.neulet.2017.07.048. Epub 2017 Jul 28.
RGD ID: 13506777
Pubmed: PMID:28757391   (View Abstract at PubMed)
DOI: DOI:10.1016/j.neulet.2017.07.048   (Journal Full-text)

Painful diabetic neuropathy (PDN) is a common complication of diabetes mellitus. However, the treatment for PDN is limited in clinical practice. In the present study, we investigated the effect of systemic administration dexmedetomidine (DEX), a selective alpha 2 adrenergic receptor (α2AR) agonist, on mechanical allodynia and its underlying mechanism in db/db mice, an animal model of type 2 diabetes mellitus. Our data demonstrated that db/db mice develop mechanical allodynia at the early stage of diabetes. During the period of mechanical allodynia, we detected increased release of norepinephrine (NE) and decreased levels of α2A-Adrenoceptors in db/db mice. Immunohistochemistry showed that the α2A-Adrenoceptor is predominantly expressed in neurons in the spinal cord. Acute injection of dexmedetomidine significantly decreased mechanical allodynia, which was blocked by its selective antagonist BRL44408. Furthermore, the upregulation of pERK1 and pERK2 in db/db mice were attenuated by preadministration of dexmedetomidine. We provide the first evidence that the functional alternation of spinal noradrenergic system might underlie exaggerated nociception in PDN. Systemic dexmedetomidine inhibits the mechanical allodynia which is related to ERK signaling pathway in type 2 diabetes, implying that the α2-Adrenoceptor might be a potential therapeutic strategy for PDN.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
MAPK1Humantype 2 diabetes mellitus  ISOMapk1 (Mus musculus)protein:increased expression:dorsal horn:RGD 
MAPK3Humantype 2 diabetes mellitus  ISOMapk3 (Mus musculus)protein:increased expression:dorsal horn:RGD 
Mapk1Rattype 2 diabetes mellitus  ISOMapk1 (Mus musculus)protein:increased expression:dorsal horn:RGD 
Mapk1Mousetype 2 diabetes mellitus  IEP protein:increased expression:dorsal horn:RGD 
Mapk3Rattype 2 diabetes mellitus  ISOMapk3 (Mus musculus)protein:increased expression:dorsal horn:RGD 
Mapk3Mousetype 2 diabetes mellitus  IEP protein:increased expression:dorsal horn:RGD 

Objects Annotated

Genes (Rattus norvegicus)
Mapk1  (mitogen activated protein kinase 1)
Mapk3  (mitogen activated protein kinase 3)

Genes (Mus musculus)
Mapk1  (mitogen-activated protein kinase 1)
Mapk3  (mitogen-activated protein kinase 3)

Genes (Homo sapiens)
MAPK1  (mitogen-activated protein kinase 1)
MAPK3  (mitogen-activated protein kinase 3)


Additional Information